Current and historical daily PE Ratio for Novo Nordisk A/S (
) from 1990 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Novo Nordisk A/S stock (NVO) PE ratio as of Jun 04 2024 is 47.65.
More Details
Novo Nordisk A/S (NVO) PE Ratio (TTM) Chart
Novo Nordisk A/S (NVO) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1242
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Novo Nordisk A/S PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-04 | 47.8 | 2024-04-01 | 44.1 |
| 2024-06-03 | 46.9 | 2024-03-28 | 44.4 |
| 2024-05-31 | 46.8 | 2024-03-27 | 47.5 |
| 2024-05-30 | 46.0 | 2024-03-26 | 48.0 |
| 2024-05-29 | 45.9 | 2024-03-25 | 47.9 |
| 2024-05-28 | 46.4 | 2024-03-22 | 47.8 |
| 2024-05-24 | 47.1 | 2024-03-21 | 48.2 |
| 2024-05-23 | 46.9 | 2024-03-20 | 48.4 |
| 2024-05-22 | 46.4 | 2024-03-19 | 48.8 |
| 2024-05-21 | 46.8 | 2024-03-18 | 49.4 |
| 2024-05-20 | 46.0 | 2024-03-15 | 49.1 |
| 2024-05-17 | 45.6 | 2024-03-14 | 50.0 |
| 2024-05-16 | 46.0 | 2024-03-13 | 49.6 |
| 2024-05-15 | 46.6 | 2024-03-12 | 50.2 |
| 2024-05-14 | 46.0 | 2024-03-11 | 48.7 |
| 2024-05-13 | 45.8 | 2024-03-08 | 49.4 |
| 2024-05-10 | 44.4 | 2024-03-07 | 50.5 |
| 2024-05-09 | 44.5 | 2024-03-06 | 46.3 |
| 2024-05-08 | 43.8 | 2024-03-05 | 46.3 |
| 2024-05-07 | 44.0 | 2024-03-04 | 47.5 |
| 2024-05-06 | 43.1 | 2024-03-01 | 46.1 |
| 2024-05-03 | 42.6 | 2024-02-29 | 44.5 |
| 2024-05-02 | 42.9 | 2024-02-28 | 45.1 |
| 2024-05-01 | 44.7 | 2024-02-27 | 45.4 |
| 2024-04-30 | 44.4 | 2024-02-26 | 45.9 |
| 2024-04-29 | 43.9 | 2024-02-23 | 45.8 |
| 2024-04-26 | 43.9 | 2024-02-22 | 46.2 |
| 2024-04-25 | 43.5 | 2024-02-21 | 44.9 |
| 2024-04-24 | 43.6 | 2024-02-20 | 45.1 |
| 2024-04-23 | 44.5 | 2024-02-16 | 46.0 |
| 2024-04-22 | 43.3 | 2024-02-15 | 45.2 |
| 2024-04-19 | 42.5 | 2024-02-14 | 45.8 |
| 2024-04-18 | 42.5 | 2024-02-13 | 44.6 |
| 2024-04-17 | 43.1 | 2024-02-12 | 44.8 |
| 2024-04-16 | 42.7 | 2024-02-09 | 45.0 |
| 2024-04-15 | 42.9 | 2024-02-08 | 44.0 |
| 2024-04-12 | 43.1 | 2024-02-07 | 44.1 |
| 2024-04-11 | 43.4 | 2024-02-06 | 43.7 |
| 2024-04-10 | 43.2 | 2024-02-05 | 43.9 |
| 2024-04-09 | 43.2 | 2024-02-02 | 42.2 |
| 2024-04-08 | 44.1 | 2024-02-01 | 43.0 |
| 2024-04-05 | 43.5 | 2024-01-31 | 42.6 |
| 2024-04-04 | 42.9 | 2024-01-30 | 40.5 |
| 2024-04-03 | 43.9 | 2024-01-29 | 40.5 |
| 2024-04-02 | 43.8 | 2024-01-26 | 40.1 |
Novo Nordisk A/S (NVO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Novo Nordisk A/S
NAICS : 325412
SIC : 2836
ISIN : US6701002056
Share Class Description:
NVO: ADRCompare
Compare
Traded in other countries / regions
NVO.USANOVO B.Denmark0QIU.UKNOV.GermanyN1VO34.BrazilNVO.MexicoNNO2.Austria IPO Date
1981-07-09Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers